• A Company Dedicated to Safe Therapeutic Modulation of Monoamine Neurotransmitter

  • Reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensin

  • Annual report 2023

    May 2, 2024

  • Interim Report January – March 2024

    May 10, 2024


Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %

Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.

CEO letter

I am delighted to provide an update on Initiator Pharma’s progress and achievements during the start of 2024, building upon previous year’s successes where we achieved multiple important milestones across our development pipeline. We have continued to advance our goal of progressing novel drug candidates toward the market in a cost and time effective way, for the benefit of both patients in need of improved medical therapies and for our shareholders, while also strengthening our position in the market.


Monoamine transporters is a unique class of proteins that are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. Our unique monoamine reupdate inhibitors are targeting the monoamine transporters to increase the levels of monoamine transmitters in diseases.